IMPROVE-IT Trial Ezetimibe

<p>Dec 24, 2014 01:04 PM</p>

<p>

non-statins ... no benfit...</p>

<p>

ezetim inhibits intes absorp of choles.</p>

<p>

eze can further reduce LDL by 20%.</p>

<p>

can ezet further reduce cardiac events?

is lower better with LDLc.</p>

<p>

STEMI/NSTEMI UA pts.</p>

<p>

pts followed for avg 6 yrs... min 2.5 yrs.</p>

<p>

primary: &nbsp;all death, MI, US, cor revasc, stroke...</p>

<p>

LDLc &nbsp;53 &nbsp;vs 70...</p>

<p>

7 year event rates: &nbsp;&nbsp;32.7% vs &nbsp;34.7 % &nbsp;&nbsp;HR &nbsp;0.936 &nbsp;p 0.016.</p>

<p>

LOOK at Table on page 7 ! &nbsp;(barely any change)</p>

<p>

all cause dath: &nbsp;15.4% &nbsp;vs &nbsp;15.3 %

CV death &nbsp;6.9% vs 6.8%

CHD death &nbsp;5.7 vs 5.8

MI &nbsp;13.1 vs 14.8%</p>

<p>

tiny diffs &nbsp;(need to add them up to get signif!)

CV death + MI + stroke &nbsp;21.8% vs 23.4% &nbsp;0.90 HR...</p>

<p>

comments:

are we to applaud and celebrate a 6% relative risk reduction... driven

by nonfatal end points? &nbsp;(no!)</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;

&nbsp;</p>